spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  leuprolide 

 HSMN NewsFeed - 12 May 2021
Centers for Medicare and Medicaid Services (CMS) Issues Permanent J-Code for Tolmar's FENSOLVI(R) Effective July 1, 2021
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 4 May 2020
Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 4 May 2020
FDA Approves FENSOLVI(R) (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2020
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 11 Feb 2019
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Sep 2017
Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 31 Jul 2017
Foresee Pharmaceuticals Announces CEO Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2017
Foresee Pharmaceuticals Announces Key Executive Appointments
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 5 Apr 2017
Foresee Pharmaceuticals Announces Completion of USD16M Fundraising
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Jan 2017
Foresee Pharmaceuticals Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2012
FIRMAGON(R) (degarelix) demonstrates non-inferiority to goserelin with bicalutamide in reducing prostate volume in prostate cancer patients while providing better relief from lower urinary tract symptoms
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 27 Feb 2012
European Commission Approves Esmya(R) for the Pre-Operative Treatment of Uterine Fibroids (myomas)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Jun 2011
Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot(R) (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 2 Jun 2011
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2011
Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2009
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Aug 2009
Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Biopharmaceuticals
 HSMN NewsFeed - 18 Mar 2009
FIRMAGON(R) (Degarelix) is Launched in Europe for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2009
Sanofi-aventis and AEterna Zentaris Sign Agreement in the U.S.
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 4 Mar 2009
Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2009
European Commisssion Grants Ferring Pharmaceuticals Approval of FIRMAGON(R) (Degarelix) for Treatment of Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jan 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2008
DOR BioPharma Forms orBec(R) European Medical Advisory Board
Biopharmaceuticals
 HSMN NewsFeed - 26 Aug 2008
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 23 May 2008
DOR BioPharma Opens New Corporate Office in United Kingdom
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2008
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
Biopharmaceuticals
 HSMN NewsFeed - 27 Mar 2008
Positive Phase III Data Unveiled for New GnRH Blocker Degarelix
Biopharmaceuticals Urology
 HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Mar 2008
Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 20 Dec 2007
Marketing of Viadur(R) (leuprolide acetate implant) to Phase Out by April 2008
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2007
DOR BioPharma Receives Not Approvable Letter From FDA for orBec(R) for Treatment of Gastrointestinal Graft-versus-Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Biopharmaceuticals
 HSMN NewsFeed - 31 Aug 2007
Eligard(R) six-month formulation successfully completes European approval procedure
Biopharmaceuticals Drug Delivery Regulatory Oncology
 HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 26 Feb 2007
Takeda and TAP to Promote Sucampo's AMITIZA(R) in the United States
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 24 Jan 2007
DURECT Amends Agreement with Voyager Governing Memryte(TM)
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 8 Jan 2007
Neurocrine Biosciences Announces Positive Results From Second Phase II Study With Its Orally Active GnRH Receptor Antagonist in Endometriosis
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2006
Eligard(R) six-month formulation approved in Germany
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Oct 2006
Repros Reports Partial Interim Assessment of Phase 2 Study of Proellex(TM) in Endometriosis
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
TAP Enters Into Co-Promotion Agreement for Famvir(R)
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Leuprolide Acetate Stabilizes Cognitive and Functional Decline in Women With Alzheimer's Disease, Study Shows
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 May 2006
Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study for Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Apr 2006
Valera Pharmaceuticals Completes Phase III Study of Its Twelve-Month Implant for Treating Central Precocious Puberty
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 23 Jan 2006
U.S. Federal Trade Commission Clears Teva/IVAX Merger
Biopharmaceuticals Mergers & Acquisitons
 HSMN NewsFeed - 16 Jan 2006
Joseph DeVeaugh-Geiss, M.D., Expands Role as Interim Chief Medical Officer at Voyager Pharmaceutical Corporation
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 46

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 46 additional stories matching:
leuprolide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.